Inhaled Insulin

A Clinical and Historical Review

Jason Chan, Angela Cheng-Lai

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Insulin is the most effective blood glucose lowering agent and remains one of the cornerstones of diabetes management. However, many individuals with diabetes are either reluctant to initiate or are nonadherent to their insulin therapy for various reasons, including fear of frequent injections. Technosphere Insulin (TI) is a novel inhaled insulin powder that is approved by the United States Food and Drug Administration for the management of diabetes. The results from 2 phase III clinical trials have shown that TI was noninferior to subcutaneous insulin aspart and superior to inhaled placebo in lowering HbA1c in patients with diabetes mellitus types 1 and 2, respectively. Across both studies, TI appears to be generally well tolerated, with the most common adverse events being hypoglycemia and cough. However, long-term pulmonary safety concerns have not been addressed and additional studies are needed. Overall, TI appears to be a promising noninvasive prandial insulin alternative for individuals with diabetes who are at risk for medication nonadherence due to aversion to frequent injections. This article provides a review of the historical development of TI, its safety and efficacy data, and its advantages and disadvantages over traditional injectable insulins.

Original languageEnglish (US)
Pages (from-to)140-146
Number of pages7
JournalCardiology in Review
Volume25
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Insulin
Injections
Insulin Aspart
Insulins
Safety
Phase III Clinical Trials
Medication Adherence
United States Food and Drug Administration
Type 1 Diabetes Mellitus
Hypoglycemia
Cough
Powders
Type 2 Diabetes Mellitus
Fear
Meals
Blood Glucose
Placebos
Lung

Keywords

  • Afrezza
  • diabetes
  • history
  • inhaled insulin
  • technosphere

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Inhaled Insulin : A Clinical and Historical Review. / Chan, Jason; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 25, No. 3, 2017, p. 140-146.

Research output: Contribution to journalReview article

@article{7c4add7b3f624b8eabba98485b122d73,
title = "Inhaled Insulin: A Clinical and Historical Review",
abstract = "Insulin is the most effective blood glucose lowering agent and remains one of the cornerstones of diabetes management. However, many individuals with diabetes are either reluctant to initiate or are nonadherent to their insulin therapy for various reasons, including fear of frequent injections. Technosphere Insulin (TI) is a novel inhaled insulin powder that is approved by the United States Food and Drug Administration for the management of diabetes. The results from 2 phase III clinical trials have shown that TI was noninferior to subcutaneous insulin aspart and superior to inhaled placebo in lowering HbA1c in patients with diabetes mellitus types 1 and 2, respectively. Across both studies, TI appears to be generally well tolerated, with the most common adverse events being hypoglycemia and cough. However, long-term pulmonary safety concerns have not been addressed and additional studies are needed. Overall, TI appears to be a promising noninvasive prandial insulin alternative for individuals with diabetes who are at risk for medication nonadherence due to aversion to frequent injections. This article provides a review of the historical development of TI, its safety and efficacy data, and its advantages and disadvantages over traditional injectable insulins.",
keywords = "Afrezza, diabetes, history, inhaled insulin, technosphere",
author = "Jason Chan and Angela Cheng-Lai",
year = "2017",
doi = "10.1097/CRD.0000000000000143",
language = "English (US)",
volume = "25",
pages = "140--146",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Inhaled Insulin

T2 - A Clinical and Historical Review

AU - Chan, Jason

AU - Cheng-Lai, Angela

PY - 2017

Y1 - 2017

N2 - Insulin is the most effective blood glucose lowering agent and remains one of the cornerstones of diabetes management. However, many individuals with diabetes are either reluctant to initiate or are nonadherent to their insulin therapy for various reasons, including fear of frequent injections. Technosphere Insulin (TI) is a novel inhaled insulin powder that is approved by the United States Food and Drug Administration for the management of diabetes. The results from 2 phase III clinical trials have shown that TI was noninferior to subcutaneous insulin aspart and superior to inhaled placebo in lowering HbA1c in patients with diabetes mellitus types 1 and 2, respectively. Across both studies, TI appears to be generally well tolerated, with the most common adverse events being hypoglycemia and cough. However, long-term pulmonary safety concerns have not been addressed and additional studies are needed. Overall, TI appears to be a promising noninvasive prandial insulin alternative for individuals with diabetes who are at risk for medication nonadherence due to aversion to frequent injections. This article provides a review of the historical development of TI, its safety and efficacy data, and its advantages and disadvantages over traditional injectable insulins.

AB - Insulin is the most effective blood glucose lowering agent and remains one of the cornerstones of diabetes management. However, many individuals with diabetes are either reluctant to initiate or are nonadherent to their insulin therapy for various reasons, including fear of frequent injections. Technosphere Insulin (TI) is a novel inhaled insulin powder that is approved by the United States Food and Drug Administration for the management of diabetes. The results from 2 phase III clinical trials have shown that TI was noninferior to subcutaneous insulin aspart and superior to inhaled placebo in lowering HbA1c in patients with diabetes mellitus types 1 and 2, respectively. Across both studies, TI appears to be generally well tolerated, with the most common adverse events being hypoglycemia and cough. However, long-term pulmonary safety concerns have not been addressed and additional studies are needed. Overall, TI appears to be a promising noninvasive prandial insulin alternative for individuals with diabetes who are at risk for medication nonadherence due to aversion to frequent injections. This article provides a review of the historical development of TI, its safety and efficacy data, and its advantages and disadvantages over traditional injectable insulins.

KW - Afrezza

KW - diabetes

KW - history

KW - inhaled insulin

KW - technosphere

UR - http://www.scopus.com/inward/record.url?scp=85017408911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017408911&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000143

DO - 10.1097/CRD.0000000000000143

M3 - Review article

VL - 25

SP - 140

EP - 146

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -